Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
- PMID: 14551143
- DOI: 10.1182/blood-2003-06-2031
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Abstract
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action. Here, we show that certain of these reagents (rituximab and 1F5), which redistribute CD20 into membrane rafts, are bound efficiently by C1q, deposit C3b, and result in complement-dependent cytotoxicity (CDC). This activity is important in vivo, because complement depletion using cobra venom factor (CVF) markedly reduced the efficacy of rituximab and 1F5 in 2 lymphoma xenograft models. However, complement depletion had no effect on the potent therapeutic activity of B1, a mAb that does not redistribute CD20 into membrane rafts, bind C1q, or cause efficient CDC. Equivalent immunotherapy also occurred in the presence or absence of natural killer (NK) cells. Perhaps most surprising was the observation that F(ab')2 fragments of B1 but not 1F5 were able to provide substantial immunotherapy, indicating that non-Fc-dependent mechanisms are involved with B1. In accordance with this, B1 was shown to induce much higher levels of apoptosis than rituximab and 1F5. Thus, although complement is important for the action of rituximab and 1F5, this is not so for B1, which more likely functions through its ability to signal apoptosis.
Similar articles
-
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.Cancer Immunol Immunother. 2002 Mar;51(1):15-24. doi: 10.1007/s00262-001-0247-1. Epub 2001 Dec 18. Cancer Immunol Immunother. 2002. PMID: 11845256 Free PMC article.
-
A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.Cancer Immunol Immunother. 2010 Dec;59(12):1791-800. doi: 10.1007/s00262-010-0905-2. Epub 2010 Aug 17. Cancer Immunol Immunother. 2010. PMID: 20714721 Free PMC article.
-
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.Blood. 2008 Nov 15;112(10):4170-7. doi: 10.1182/blood-2008-04-149161. Epub 2008 Jun 26. Blood. 2008. PMID: 18583569 Free PMC article.
-
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.Oncologist. 2008 Sep;13(9):954-66. doi: 10.1634/theoncologist.2008-0089. Epub 2008 Sep 8. Oncologist. 2008. PMID: 18779537 Review.
-
The mechanisms of action of rituximab in the elimination of tumor cells.Semin Oncol. 2003 Feb;30(1 Suppl 2):3-8. doi: 10.1053/sonc.2003.50025. Semin Oncol. 2003. PMID: 12652458 Review.
Cited by
-
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Mol Cancer Ther. 2013 Apr;12(4):416-26. doi: 10.1158/1535-7163.MCT-12-0731. Epub 2013 Jan 31. Mol Cancer Ther. 2013. PMID: 23371858 Free PMC article.
-
Obinutuzumab for the treatment of indolent lymphoma.Future Oncol. 2016 Aug;12(15):1769-81. doi: 10.2217/fon-2016-0084. Epub 2016 Apr 27. Future Oncol. 2016. PMID: 27117452 Free PMC article. Review.
-
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.Blood. 2006 Oct 15;108(8):2648-54. doi: 10.1182/blood-2006-04-020057. Epub 2006 Jul 6. Blood. 2006. PMID: 16825493 Free PMC article.
-
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Blood. 2008 Feb 1;111(3):1456-63. doi: 10.1182/blood-2007-02-074716. Epub 2007 Nov 16. Blood. 2008. PMID: 18024795 Free PMC article.
-
Function-first antibody discovery: Embracing the unpredictable biology of antibodies.Oncoimmunology. 2013 Aug 1;2(8):e25047. doi: 10.4161/onci.25047. Epub 2013 May 20. Oncoimmunology. 2013. PMID: 24083074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical